Logo

AbbVie Reports the US FDA's Acceptance of BOTOX's sBLA for Pediatric Patients with Neurogenic Detrusor Overactivity

Share this

AbbVie Reports the US FDA's Acceptance of BOTOX's sBLA for Pediatric Patients with Neurogenic Detrusor Overactivity

Shots:

  • The US FDA has accepted the Allergan’s sBLA to expand the BOTOX prescribing information for treating detrusor (bladder muscle) overactivity associated with an underlying neurologic condition in pediatric patients aged 5 -17yrs who have an inadequate response to or are intolerant of- or for any reason unwilling to continue anticholinergic medication
  • The sBLA is based on P-III study assessing BOTOX in 100+ pediatric patients with neurogenic detrusor overactivity and a long-term extension study. The company anticipates the PDUFA date to be in Q1’21 following a standard 10-mos. review
  • BOTOX is the first and only neurotoxin approved to treat leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition in adults who still have leakage or cannot tolerate the side effects after trying an anticholinergic medication

Click here to read full press release/ article 

Ref: AbbVie | Image:abbvie


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions